Table 1.

Summary of the studies reporting SARS-CoV-2 variants in immunocompromised COVID-19 patients.

Name of the study	Age and clinical diagnosis	CCP regimen	Outcome	Mutation (s)
Chen et al. [19]	50 y; post kidney transplant	High titre CCP on day 1 of the admission	The patient became SARS-CoV-2 negative on day 45 of admission However, the patient died on day 94	5 different mutations in S protein on 21st day nasopharyngeal sample suggesting in host viral evolution
Kemp et al. [20]	70 y, B cell lymphoma	CCP therapy on day 57	The patient died on day 102	Mutations in spike protein after day 65
Bazykin et al. [21]	47 y, non-Hodgkin diffuse B cell lymphoma	CCP not used in management	The patient recovered after 120 days	140 deletions in spike – N terminal domain protein region
Borges et al. [22]	61 y, non-Hodgkin diffuse B cell lymphoma	CCP not used in the management	The patient was SARS-CoV-2 negative after 196 days	A total of 18 mutations had accumulated by day 164 Total 17 mutations in spike protein
Troung et al. [23]	3 y, ALL	CCP not used in the management	SARS-CoV-2 negative after 46 days	Multiple mutations in spike protein
	21 y, ALL	1 st CCP on day 103. Thereafter weekly CCP till day 144 and every alternate week after that	Patient was still SARS-CoV-2 positive on day 250 at the time of publication of the manuscript	Multiple mutations in spike protein both before and after CCP
	2 y, ALL	CCP not used in the management	Patient was SARS-CoV-2 negative on day 196	Multiple mutations in spike protein
Avanzato et al. [4]	71 y, CLL	2 course of CCP, 1st on day 70 2nd on day 95	SARS-CoV-2 negative after 105 days	Multiple mutations in spike protein; the majority of mutations had already occurred before the initiation of CCP
Choi et al. [24]	45 y, APS	Monoclonal antibodies given on day 143	The patient died on day 152	Multiple mutations in spike protein, majority of mutations had already occurred before initiation of monoclonal antibody therapy
Khatamzas et al. [25]	70 y, B-cell depleted lymphoma	CCP initiated on approximately day 40 of diagnosis	The patient died after 5 months of diagnosis	Multiple mutations in spike protein, the frequency of mutations increased after administration of CCP
Pommeret et al. [26]	5 patients with B-cell malignancies	Monoclonal antibodies given within 5 days of their first symptom	4 patients recovered after 38 to 63 days of diagnosis; 1 patient died after 56 days of diagnosis	Mutation in spike protein detected in 4 out of 5 patients after administration of monoclonal antibodies

APS: antiphospholipid syndrome; ALL: acute lymphoblastic leukemia; CLL: chronic lymphoblastic leukemia; CCP: COVID-19 convalescent plasma; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.